ASCO GU 2022: Key Takeaways in Prostate Cancer Imaging

Welcome to GU Oncology Now’s expert roundtable series, where we feature in-depth, and captivating conversations focused on advancements in genitourinary cancer treatment from premier practicing minds in the GU cancer space. Moderating this series is Daniel George, MD. He is accompanied by an expert panel, including Oliver Sartor, MD, Preston C. Sprenkle, MD, and Rana R. McKay, MD. Together, they discussed cutting-edge therapies for advanced prostate cancer.

Additional PSMA Therapies Being Studied

video
In this final segment, the panel discussed additional PSMA-targeting agents currently being assessed. While the main topic of this series has focused on PSMA-617-Lutetium-177 (assessed in the VISION trial), Dr. Oliver Sartor mentioned PSMA-I&T-Lutetium-177, which represents a different moiety for binding to PSMA. Moreover,...
video

Additional PSMA Therapies Being Studied

In this final segment, the panel discussed additional PSMA-targeting agents currently being assessed. While the main topic of this series has focused on PSMA-617-Lutetium-177...
video

Is Lutetium-177 “Perfect”?

In this segment, Dr. Oliver Sartor gave his honest take on Lutetium-177 PSMA at a treatment. The basis: some patients respond well to it,...
video

Limitations of Lutetium-177-PSMA & Addressing Treatment Challenges

In this segment, Dr. Oliver Sartor discussed some limitations (and advantages) of Lutetium-177-PSMA. The treatment, according to Dr. Sartor, induces positive responses in lymph...
video

The Palliative Benefits of Lutetium-177-PSMA

In this segment, Dr. Daniel George asked Dr. Rana R. McKay to discuss the palliative benefits of Lutetium-177 PSMA. Dr. McKay explained that, with...
video

Experience with PSMA PET Imaging

In this segment, series moderator Dr. Daniel George spoke to Dr. Preston C. Sprenkle about his experience with PSMA PET scans. Dr. Sprenkle noted...
video

A Look at Lutetium-177-PSMA & Analyzing the VISION Study

In this segment, the roundtable panel, led by Dr. Daniel George (Duke University), began an “inspiring discussion” around lutetium-177-PSMA for the treatment of advanced...

The Panel

Daniel George, MD

Professor of Medicine and Surgery, Duke University School of Medicine

Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine.  He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology disease-based group and is co-lead of the DCI Center for Prostate and Urologic Cancers.  He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 200 peer-reviewed publications.  His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and cancer disparities. He has led efforts defining the clinical benefit of VEGF receptor targeted therapy in renal cell carcinoma in both the metastatic and in the adjuvant setting. In addition, Dr George has championed studies evaluating the outcomes of novel hormonal agents by race in metastatic castration resistant prostate cancer.

Rana R. McKay, MD

Associate Professor of Medicine and Urology, University of California San Diego

Dr. McKay is an Associate Professor of Medicine and Urology at the University of California San Diego and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center. She is a board-certified medical oncologist who specializes in treating people with urogenital cancers, including bladder, kidney, prostate, and testicular cancer. Her research interests include the design and implementation of clinical trials to advance the treatment of patients with urologic cancers.

Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency in Internal Medicine at Johns Hopkins Hospital. She completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute, Harvard Medical School. She went on to serve as an Assistant Professor at Harvard Medical School and a medical oncologist at Dana-Farber/Brigham and Women’s Cancer Center in Boston before joining UC San Diego Health.

Preston C. Sprenkle, MD

Associate Professor of Urology, Yale University School of Medicine

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma – a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.

Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis and  treatment. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors in the prostate.

Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.

Oliver Sartor, MD

Associate Dean for Oncology, Tulane University School of Medicine

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three phase III studies pivotal for FDA approval. He has lectured widely, and at last count has given invited lectures in 33 countries.

He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology) and is co-PI of the VISION trial, an international phase III study of Lu-177 PSMA in advanced prostate cancer.